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A Ab bs st tr ra ac ct t
The message is loud and clear. MicroRNA-96, one in a cluster of three related neurosensory
microRNAs, is crucial to the development and maintenance of inner ear hair cells and hearing in
mice and humans. Two recent studies show that mutations in the critical seed region of the
microRNA underlie the cause of hair cell degeneration and progressive hearing loss. Other recent
reports reveal the general requirement of microRNAs for sensory epithelial development and
maintenance in Dicer knockout mouse ear. The challenge begins to determine whether microRNAs
will resonate as therapeutic agents or target molecules to preserve or restore hearing.
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S So om me et th hi in ng g   t to o   h he ea ar r   a ab bo ou ut t
MicroRNAs (miRNAs) have made quite a clatter since their
widespread eukaryotic distribution, evolutionary conser-
vation, and biological significance have become apparent in
recent years [1,2]. These small RNAs function to post-
transcriptionally repress target messenger RNA (mRNA)
expression, often producing subtle changes in protein
expression [3,4]. Nevertheless, the net effect levied by
individual or combined miRNA function contributes sub-
stantially to normal processes in development and aberrant
processes in disease. Such is the case in cancer biology [5],
where changes in miRNA expression or mutations affecting
miRNA function underlie biological mechanisms supporting
cell growth, suggesting that miRNAs might serve as effica-
cious agents or target molecules in treating disease.
Chances are that you have heard the clatter, the literal fact of
which can be attributed in part to miRNA function in
mechanosensory hair cells of the inner ear. Two recent studies
published in Nature Genetics show that mutations in miRNA-
96 (miR-96) are responsible for non-syndromic progressive
hearing loss in humans and mice [6,7]. These studies
importantly establish the first known Mendelian disease
associated with miRNA function, and place a miRNA gene
among the ranks of more than 100 other genetic loci associated
with heritable deafness or hearing impairment [8], reflecting
the anatomical and functional complexity of the inner ear.
miR-96 is one in a cluster of three related miRNAs in
vertebrate organisms that additionally includes miR-182 and
miR-183 (miR-96/182/183) [9]. These conserved miRNAs
are processed from a common primary transcript [10-12]
and are thus co-expressed in neurosensory cells and organs,
including photoreceptor cells in the eye and hair cells in the
ear [10,11,13]. Moreover, they are homologous in sequence
to one another and to other miRNAs (miR-228 and
miR-263b) exhibiting neurosensory expression in inverte-
brate organisms [14]. The strong evolutionary conservation
and neurosensory expression of the broader family suggest
that these miRNAs play critical roles in the development and
function of sensory cells. Nevertheless, each miRNA
possesses a distinct sequence difference in its seed region,
the portion of the miRNA (nucleotides 2 to 8) that interacts
with target mRNAs [15], implying the miRNAs serve non-
overlapping functions that are further expected to depend
upon target gene expression in specific cell types.S Si il le en nc ci in ng g   e ef ff fe ec ct t   o of f   o on ne e   m mi iR RN NA A
The significance of miR-96 expression and function in
mechanosensory hair cells of the inner ear is revealed and
fortified by both the similarity and distinction of results from
genetic studies of mouse and human progressive hearing
loss. Lewis et al. [7] report their findings on the diminuendo
(Dmdo) mouse, a semidominant mutant allele identified in a
screen for genes that cause deafness. The allele mapped to a
region of chromosome 6 that includes the miR-96 gene
(Mirn96), in which an A-to-T transversion affects the corres-
ponding mutation at position 7 of the mature miRNA within
the seed sequence (Figure 1a). Heterozygous Dmdo mutants
exhibit a progressive and substantial hearing loss that
correlates with stereocilia degeneration and auditory hair
cell loss in the cochlea, whereas homozygous Dmdo mutants
exhibit earlier degeneration leading to complete hair cell loss
and profound deafness. In situ hybridization detecting the
mature miRNA demonstrates that the mutation does not
affect processing, suggesting that mutant miR-96 might
cause hearing loss through a concomitant loss of function
and gain of function.
Congruent with the mouse study, Mencía et al. [6] report
their further analysis of a human autosomal dominant
deafness locus (DFNA50) that mapped to a region of
chromosome 7 that includes the miR-96 gene (MIR96) [16].
Analysis of the original DFNA50 family and hundreds of
other genetically undiagnosed hearing-impaired families
and normal hearing controls established two families with
distinct mutations in miR-96 that segregate with the hearing
loss phenotype [6]. Each affected family member possesses
either a G-to-A transition or C-to-A transversion that respec-
tively affects the corresponding mutation at position 5 or 6
of the mature miRNA within the seed sequence (Figure 1a).
In vitro analysis demonstrates that the mutations affect
processing and substantially diminish production of mature
miRNA, suggesting that the hearing loss in humans is caused
largely by miRNA loss of function. Overall, the commonality
of hearing loss effected by different mouse and human
mutations in the seed region of miR-96 [6,7] strongly
suggests the phenotype is caused by miRNA loss of function
rather than gain of function per se. Moreover, the effect of
miR-96 haploinsufficiency suggests that hair cells are
extremely sensitive to perturbation of miRNA levels and that
miR-96 is a dynamic regulator of hair cell gene expression.
Both studies [6,7] examined the influence of miR-96 on a
common set of predicted target genes expressed in the inner
ear, including Aqp5 (an aquaporin), Celsr2 (a cadherin),
Myrip (a myosin-interacting protein), Odf2 (a component of
cilia), and Ryk (an orphan receptor associated with ephrin
receptors).  In vitro analysis demonstrates that miR-96
effects a mild but significant reduction in expression of
predicted target-reporter gene constructs that is not repro-
duced by mutant miR-96 [6,7]. However, immunohisto-
chemical analysis in diminuendo mouse provided no
evidence for changes in protein levels [7]. The results are
consistent with proteomic and transcriptomic studies show-
ing that miRNAs effect many mild changes in target gene
expression [3,4] that might not be detectible by less sensitive
methodologies. Nevertheless, microarray analysis of gene
expression in normal and diminuendo mouse cochlear
sensory epithelium (that is, organ of Corti) demonstrates
that changes in transcript levels correlate with miR-96 loss
of function and mutant miR-96 gain of function [7]. Assess-
ment using the Sylamer algorithm [17] shows that transcripts
upregulated in diminuendo mouse are relatively enriched for
complementary seed matches to miR-96, consistent with loss
of function, whereas downregulated transcripts are relatively
enriched for complementary seed matches to mutant miR-96,
consistent with gain of function [7].
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MicroRNA-96 mutations effect changes in hair cell gene expression, hair
cell degeneration and progressive hearing loss. ( (a a) ) MicroRNA-96
sequence and mutations within the seed region (blue) found in humans
(green) and the diminuendo mouse (red). ( (b b) ) The balance of hair cell gene
expression is offset by the diminuendo mutation in miR-96, where
primary effects on target gene expression appear less in magnitude than
secondary effects on the expression of other genes crucial to hair cell
function. ( (c c) ) Loss of crucial hair cell protein expression in diminuendo
mouse contributes to hair cell degeneration and ultimate demise. The
normal subcellular localization of hair cell proteins absent in diminuendo
mouse is indicated.
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gene expression (primary effects) are changes in the expres-
sion of other genes that do not possess complementary seed
matches to normal or mutant miR-96 (secondary effects;
Figure 1b). Immunohistochemical analysis of diminuendo
mouse hair cells [7] shows drastic reduction in expression of
genes crucial to hair cell function and survival, including
Ptprq (required for stereocilia maturation), Ocm (calcium
ion binding), Prestin (hair cell motor protein), and Gfi1 (hair
cell transcription factor) (Figure 1c). Such results are not
general features of degenerating hair cells in other mutant
mouse models [7], suggesting that miR-96 specifically regu-
lates a complex network of pathways supporting hair cell
development, maturation and survival.
Considering the evolutionary conservation and expression of
miR-96/182/183 in neurosensory hair cells and photo-
receptors, it is noteworthy that individuals with hearing loss
affected by mutations in miR-96 show no deficit in
ophthalmologic function [6]. This suggests that each miRNA
could fulfill a substantially different role in different neuro-
sensory cells to varying degrees of functional significance.
Interestingly, targeted deletion of miR-182 was recently
reported to have no effect on the histological development of
the retina in young mice [18]. However, the effect that miR-
182 knockout has on the inner ear, or its possible functional
deficits, remain to be elucidated. Consequently, there is much
to be done to assess whether each miRNA in the miR-96/182/
183 cluster might have a differential effect in the development
and function of neurosensory cells in different organs.
G Go oo od db by ye e   m mi iR RN NA As s, ,   g go oo od db by ye e   e ea ar r
The importance of miRNAs to hair cell development and
maintenance is further corroborated by two recent studies
[19,20] that examined the effect of tissue-specific Dicer
conditional knockout (CKO), which ablates mature miRNA
production [21]. Developmentally early Dicer CKO and
depletion of miRNAs throughout the inner ear results in
severe morphohistological defects in sensory epithelia and
hair cells, where the extent of hair cell development is shown
to correlate with residual miR-183 expression [19].
Relatively later hair cell and sensory epithelium-specific
Dicer CKO results in initial formation but rapid degenera-
tion of hair cells, and deafness [20]. Interestingly, the
morphology of miRNA-depleted hair cells in each model
shows a high degree of similarity [19,20]. Results from these
studies lend further credence to the significance of miR-96/
182/183 among other hair cell miRNAs [20] in hair cell
development, maintenance and function [22].
M Mi ic cr ro om ma an na ag gi in ng g   h ha ai ir r   c ce el ll l   s su ur rv vi iv va al l   o or r   r re eg ge en ne er ra at ti io on n
The apparent biological potency of certain miRNAs such as
miR-96 poses something of a double-edged situation with
regard to their practical utility as therapeutic agents or
targets. The delivery or inhibition [23] of miRNAs could
prove efficacious or deleterious, depending on the
pharmacokinetic and pharmacodynamic properties of the
administration. One might anticipate that the use of any
such agents in situ will require methodologies for cell-
specific delivery and regulated dose and/or function to avoid
perturbing the natural balance of other miRNA-mediated
effects on the transcriptome. Nevertheless, understanding
how miRNAs manage the business of gene expression in
normal or degenerating hair cells is certain to provide routes
of discovery to novel target molecules or biological processes
that might otherwise be manipulated using traditional
small-molecule pharmaceuticals to influence hair cell
maintenance and survival. Moreover, appreciating how
miRNAs affect normal differentiation and maturation of
functional hair cells might contribute to in vivo or in vitro
methodologies for, respectively, coaxing supporting cells or
induced pluripotent stem (iPS) cells to undergo hair cell
differentiation [24]. Regardless of strategy, any utilization of
miRNAs to effect hair cell survival or regeneration is likely to
be a long story, but one that just might be worth hearing.
A Ab bb br re ev vi ia at ti io on ns s
CKO, conditional knockout; iPS, induced pluripotent stem
(cell); mRNA, messenger RNA; miRNA or miR, microRNA.
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